Charles Schwab
TXMD icon

Charles Schwab’s TherapeuticsMD TXMD Stock Holding History

Charles Schwab’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-52,726
Closed -$217K – 3624
2023
Q2 		$217K Buy
52,726
+205
+0.4% +$804 ﹤0.01% 3294
2023
Q1 		$197K Buy
52,521
+8,064
+18% +$38.7K ﹤0.01% 3158
2022
Q4 		$249K Buy
+44,457
New +$262K ﹤0.01% 3150
2022
Q2 		– Sell
-17,165
Closed -$327K – 3644
2022
Q1 		$327K Sell
17,165
-2,758
-14% -$43.4K ﹤0.01% 3200
2021
Q4 		$355K Buy
19,923
+902
+5% +$27K ﹤0.01% 3253
2021
Q3 		$706K Sell
19,021
-30,758
-62% -$1.37M ﹤0.01% 3020
2021
Q2 		$2.96M Buy
49,779
+1,989
+4% +$120K ﹤0.01% 2591
2021
Q1 		$3.2M Buy
47,790
+12,432
+35% +$973K ﹤0.01% 2511
2020
Q4 		$2.14M Buy
35,358
+6,528
+23% +$446K ﹤0.01% 2578
2020
Q3 		$2.28M Sell
28,830
-1,024
-3% -$81.6K ﹤0.01% 2454
2020
Q2 		$1.87M Buy
29,854
+2,689
+10% +$157K ﹤0.01% 2450
2020
Q1 		$1.44M Buy
27,165
+364
+1% +$36.1K ﹤0.01% 2396
2019
Q4 		$3.24M Buy
26,801
+2,967
+12% +$427K ﹤0.01% 2237
2019
Q3 		$4.33M Buy
23,834
+221
+0.9% +$31.2K ﹤0.01% 2040
2019
Q2 		$3.07M Buy
23,613
+1,123
+5% +$201K ﹤0.01% 2196
2019
Q1 		$5.48M Buy
22,490
+852
+4% +$225K ﹤0.01% 1943
2018
Q4 		$4.12M Buy
21,638
+657
+3% +$160K ﹤0.01% 2004
2018
Q3 		$6.88M Buy
20,981
+2,772
+15% +$849K ﹤0.01% 1867
2018
Q2 		$5.68M Buy
18,209
+1,009
+6% +$308K ﹤0.01% 1928
2018
Q1 		$4.19M Buy
17,200
+819
+5% +$230K ﹤0.01% 2034
2017
Q4 		$4.95M Buy
16,381
+2,548
+18% +$709K ﹤0.01% 1928
2017
Q3 		$3.66M Sell
13,833
-50
-0.4% -$14.5K ﹤0.01% 2044
2017
Q2 		$3.66M Buy
13,883
+1,357
+11% +$340K ﹤0.01% 1971
2017
Q1 		$4.51M Buy
12,526
+1,204
+11% +$373K ﹤0.01% 1817
2016
Q4 		$3.27M Buy
11,322
+591
+6% +$183K ﹤0.01% 1952
2016
Q3 		$3.65M Buy
10,731
+498
+5% +$182K ﹤0.01% 1833
2016
Q2 		$4.35M Buy
10,233
+180
+2% +$74.2K 0.01% 1657
2016
Q1 		$3.22M Buy
10,053
+1,205
+14% +$411K ﹤0.01% 1782
2015
Q4 		$4.59M Sell
8,848
-305
-3% -$113K 0.01% 1581
2015
Q3 		$2.68M Buy
9,153
+520
+6% +$185K ﹤0.01% 1898
2015
Q2 		$3.39M Buy
8,633
+245
+3% +$86.4K ﹤0.01% 1800
2015
Q1 		$2.54M Buy
8,388
+3,056
+57% +$746K ﹤0.01% 1923
2014
Q4 		$1.19M Sell
5,332
-790
-13% -$163K ﹤0.01% 2276
2014
Q3 		$1.42M Buy
6,122
+1,309
+27% +$330K ﹤0.01% 2145
2014
Q2 		$1.06M Buy
4,813
+449
+10% +$99.9K ﹤0.01% 2285
2014
Q1 		$1.38M Buy
4,364
+847
+24% +$270K ﹤0.01% 2136
2013
Q4 		$917K Buy
3,517
+841
+31% +$184K ﹤0.01% 2303
2013
Q3 		$411K Buy
2,676
+66
+3% +$7.98K ﹤0.01% 2623
2013
Q2 		$342K Buy
+2,610
New +$358K ﹤0.01% 2681

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab's TXMD Position: Q3 2023 in Review

Charles Schwab sold out of TherapeuticsMD (TXMD) in Q3 2023, closing a stake of 52,726 shares — an estimated $217K sold.

Charles Schwab first reported a position in TXMD in Q2 2013 and held it in 39 quarters. The position peaked at $6.88M in Q3 2018. 36 funds tracked by Wall St. Rank hold TXMD as of Q3 2023.

  • Charles Schwab reported no remaining TherapeuticsMD position as of Q3 2023 after selling out during the quarter.
  • Charles Schwab sold 52,726 TherapeuticsMD shares in Q3 2023, an estimated $217K.
  • Charles Schwab first reported a position in TherapeuticsMD in Q2 2013 and held it in 39 quarters.
  • Charles Schwab's TherapeuticsMD position peaked at $6.88M in Q3 2018.
  • 36 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2023.

Based on Charles Schwab's 13F filing for Q3 2023, filed 8 Nov 2023.